Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab ... system mistakenly attacks proteins in the skin’s basement membrane, leading to inflammation and skin separation.

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results ...

Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster anti-inflammatory drug Dupixent for ...